Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up

P S Hupperets; J A Wils; L Volovics; L J Schouten; M M Fickers; H N Bron; J J Jager; J M de Jong; G H Blijham

doi:10.1054/brst.2000.0180

Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up

Breast. 2001 Feb;10(1):35-7. doi: 10.1054/brst.2000.0180.

Authors

P S Hupperets¹, J A Wils, L Volovics, L J Schouten, M M Fickers, H N Bron, J J Jager, J M de Jong, G H Blijham

Affiliation

¹ Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands.

PMID: 14965556
DOI: 10.1054/brst.2000.0180

Abstract

An update with 10 years of follow up of a study adding adjuvant MPA to CAF chemotherapy is presented. A total of 409 patients were entered, of which 200 were randomized to receive 500 mg of MPA i.m. on days 1-28 and twice per week thereafter for 6 months. There was a significant improvement in metastases-free and overall survival in women >60 years of age receiving MPA (P=0.01 and P=0.02 respectively). A detrimental effect of MPA was seen in women <40 years. Possible reasons for these results are discussed.

Publication types

Clinical Trial
Randomized Controlled Trial